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Although survival rates of breast, colon, and prostate cancers are improving, deaths
from these tumors frequently occur due to metastasis. Voltage-gated Na+ channels
(VGSCs) are membrane proteins, which regulate membrane current and cellular
migration during nervous system organogenesis. VGSCs are also expressed in
fibroblasts, immune cells, glia, and metastatic cancer cells. VGSCs regulate migration
and invasion of breast, bowel, and prostate cancer cells, suggesting that they may
be novel anti-metastatic targets. We conducted a systematic review of clinical and
preclinical studies testing the effects of VGSC-inhibiting drugs in cancer. Two-hundred
and four publications were identified, of which two human, two mouse, and 20 in vitro
publications were included. In the clinical studies, the effect of these drugs on survival
and metastatic relapse is not clear. The 22 preclinical studies collectively suggest that
several VGSC-inhibiting drugs inhibit cancer proliferation, migration, and invasion. None
of the human and only six of the preclinical studies directly investigated the effect of the
drugs on VGSC activity. Studies were difficult to compare due to lack of standardized
methodology and outcome measures. We conclude that the benefits of VGSC inhibitors
require further investigation. Standardization of future studies and outcome measures
should enable meaningful study comparisons.
Keywords: anticonvulsants, breast neoplasms, colonic neoplasms, prostatic neoplasms, sodium channels
INTRODUCTION
Cancers of the breast, colon, and prostate collectively account for the majority of cancer diagnoses
in adults in the Western world (Jemal et al., 2011). Although survival rates are improving, deaths
from these cancers frequently occur due to metastasis. Metastasis is a complex process, which
involves detachment of cancer cells from the primary site, local invasion into surrounding tissues
and dissemination to distant sites in other tissues. Metastatic disease is invariably incurable, and
the molecular mechanisms underlying metastasis are not yet fully understood. Thus, there is an
urgent need to develop new molecularly targeted anti-metastatic therapies with curative intent.
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Voltage-gated Na+ channels (VGSCs) are heteromeric
membrane protein complexes made up of a single pore-
forming α subunit (Nav1.1–Nav1.9) and one or more smaller
auxiliary β subunits (β1–β4; Catterall, 2000). The β subunits
contain an extracellular immunoglobulin loop and do not form
part of the ion-conducting pore. Instead, they modulate channel
gating and function as cell adhesion molecules (Brackenbury
and Isom, 2011). The influx of Na+ ions through VGSCs is
responsible for the membrane depolarization phase underlying
action potentials in electrically excitable neurons and muscle
cells. VGSC α and β subunits have also been shown to regulate
several key aspects of organogenesis in the developing central
nervous system, including cell proliferation, neurite outgrowth,
neuronal pathfinding, and migration (Brackenbury et al., 2008a,
2010, 2013). Abnormal function of VGSCs contributes to various
excitability-related pathologies, including epilepsy, cardiac
arrhythmia, and neuropathic pain. As a result, a number of
drugs have been developed to target VGSCs (Mantegazza et al.,
2010).
Voltage-gated Na+ channels are also expressed in cells that
are traditionally considered to be “non-excitable”, including
fibroblasts, immune cells, glia, and metastatic cancer cells (Black
and Waxman, 2013). In metastatic cancer cells, including those
of the breast, bowel, and prostate, VGSCs have been shown
to potentiate a number of cellular behaviors associated with
metastasis, including migration and invasion (Brackenbury et al.,
2008b; Brackenbury, 2012; Besson et al., 2015). Furthermore,
emerging preclinical data suggest that pharmacologically
targeting VGSCs may reduce local invasion and metastasis in
mouse models (Driffort et al., 2014; Nelson et al., 2015). The
potential utility of VGSC-inhibiting agents as anti-metastatic
therapies has not surfaced in the clinic. However, the preclinical
data raise the intriguing possibility that cancer patients taking
VGSC-inhibiting medication for other pre-existing indications,
e.g., epilepsy, may have improved cancer-specific outcome
compared with those not taking such medications (Fairhurst
et al., 2014).
Although a number of recent reviews have explored the
literature relating to the contribution of VGSCs to metastasis
(Roger et al., 2006; Brackenbury and Isom, 2008; Brackenbury
et al., 2008b; Brackenbury, 2012; Fraser et al., 2014a; Besson
et al., 2015), there has been no systematic review assessing the
evidence for the potential therapeutic use of VGSC-inhibiting
agents in cancer. We therefore set out to conduct a systematic
review of the current clinical and preclinical studies that
have been performed using known VGSC-inhibiting drugs in
cancer cells. We have focused the review on cancers of the
breast, bowel, and prostate because VGSC expression has been
most extensively characterized in these tumors (Brackenbury,
2012). We have identified two clinical studies that explored
the effect of VGSC inhibitors on clinical characteristics in
cancer patients. However, the effect of these drugs on survival
and metastatic relapse is not clear. Nonetheless, our search
uncovered 22 preclinical studies collectively suggesting that
several VGSC-inhibiting drugs inhibit various aspects of the
hallmarks of cancer, including proliferation, angiogenesis, and
invasion.
MATERIALS AND METHODS
Search Strategy
A systematic literature search was performed to identify
studies using VGSC-inhibiting drugs as part of the treatment
of patients with colorectal, breast, and prostate cancer.
The databases searched were Medline and Embase (Ovid
interface) from inception until May 20th, 2015. Controlled
vocabulary and free text terms were used in these search
strategies. The search terms used were “[Sodium Channel
blocking drugs] AND [colorectal cancer or breast cancer
or prostate cancer]”. VGSC-inhibiting drugs included in
the search are in Table 1. No limits or methodological
filters were applied to these searches in order to avoid
bias. The full search strategies are listed in Supplementary
Tables S1 and S2. The protocol for the search strategy
was registered with PROSPERO (registration number
CRD42014013574).
Selection
The PRISMA guidelines were used as a basis for the selection
(Moher et al., 2009). Bibliographic details and their respective
abstracts were downloaded into EndNote. Studies were then
selected through a four-step process (Figure 1). The initial
step was the identification of the studies from EMBASE
and MEDLINE. This was achieved by reviewing the title
of each study. The second step of the process involved
identifying and removing any duplicates, removing of conference
abstracts and obvious false selections. The third step selected
TABLE 1 | Drug search terms used in systematic review.
Carbamazepine
Carbamazepine derivatives and other carboxamides
Class Ib anti-arrhythmic agents
Disopyramide
Eslicarbazepine acetate
Flecainide
Lacosamide
Lamotrigine
Lidocaine
Mexiletine
Moricizine
Oxcarbazepine
Phenytoin
Procainamide
Propafenone
Quinidine
Ranolazine
Riluzole
Rufinamide
Sodium channel blocking drugs
Sodium valproate
Tocainide
Topiramate
Valproic acid
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FIGURE 1 | Flow chart illustrating selection of studies for systematic
review. Initial exclusions were made following assessment of abstracts.
Further studies were excluded after full text assessment due to language
restrictions or study not looking at the effects of a voltage-gated Na+
channels (VGSC)-inhibiting drug listed in Table 1. The final shortlist of studies
was achieved by scoring study quality and evidence against the standardized
pre-piloted criteria in Supplementary Table S3. A minimum score of 3/5 was
required for inclusion.
manuscripts by the following inclusion criteria: the VGSC-
inhibiting drug that was used, cancer was of the breast and/or
colorectum and/or prostate, participants were over the age of
18 years. The exclusion criteria were: non-English abstract,
study not peer-reviewed. At this stage, the full text was
reviewed.
In the fourth step of the selection process, we modified
a standardized Quality Assessment Tool for Observational
Cohort and Cross-Sectional Studies (mQATSO) to quantify study
quality and evidence (Supplementary Table S3; NHLBI, 2014).
The following criteria each received a score of one: human
studies = 1, using at least one VGSC-inhibitor = 1, at least
one of the index cancers = 1, measuring cancer survival, and/or
metastasis outcome = 1, specifically investigating the VGSC-
inhibiting mode of action of the drug(s) = 1. Thus, a maximum
score of 5 could be achieved. All data were collected in a
spreadsheet in Microsoft Excel. Three reviewers (FM, CU, and
WB) screened studies independently and then discussed and
resolved discrepancies together.
RESULTS
Using search terms detailed in the section “Materials and
Methods”, 204 items were identified in EMBASE andMedline, 43
of which were duplicates and were removed. Abstract screening
excluded 22 additional records for not meeting inclusion criteria.
Full manuscript screening contained 139 items, and 115 were
excluded scoring <3/5 on quality assessment (Figure 1). Two
human and 22 preclinical in vivo and in vitro publications were
included in the final study.
The two human studies investigated a VGSC inhibitor
in one of the cancers of interest and tested drug influence
on cancer survival. However, neither of the studies tested
specifically the VGSC-inhibiting activity of the intervention
and therefore scored 4/5. Raderer et al. (1993) conducted an
observational study of quinidine as a multi-drug resistance
modifier adjuvant to pirarubicin in 14 women with metastatic
and/or refractory breast cancer to test side-effects and survival
outcomes, but an objective survival benefit was not observed.
Wheler et al. (2014) conducted a phase 1 dose finding study
of sodium valproate as adjunctive therapy to bevacizumab in
57 patients with cancer, 40 of whom had colon, breast, or
prostate cancer. They attributed the survival benefits detected
with sodium valproate to its histone deacetylase inhibition
activity, which was dose independent (Table 2), (Wheler et al.,
2014).
The remaining 22 papers scored between 3 and 4 out
of five, and all of them were preclinical studies (Figure 2).
Interestingly, four in vitro studies specifically tested the VGSC-
inhibiting mode of action of the interventions (Figure 2).
Three studies investigated prostate cancer cell lines and detected
inhibited cell growth at clinically relevant drug doses of
riluzole, sodium valproate, carbamazepine, phenytoin, and its
derivatives (Abdul and Hoosein, 2001, 2002; Anderson et al.,
2003), and one study used breast cancer cell lines and
detected reduced migration and cell invasion with phenytoin
(Yang et al., 2012). In the first study, Abdul and Hoosein
(2001) showed that carbamazepine and phenytoin both reduced
secretion of prostate-specific antigen (PSA) and interleukin-
6 (IL-6) in prostate cancer cells. They found that valproate
also inhibited PSA and IL-6 secretion to a lesser extent,
although they attributed the effect of valproate to Ca2+
channel inhibition, rather than to its possible role as a
VGSC inhibitor. All three drugs inhibited prostate cancer
cell proliferation. In a subsequent study (Abdul and Hoosein,
2002), the same authors showed that riluzole also inhibited
prostate cancer cell proliferation. However, in both studies, the
authors did not directly show whether or not functional VGSCs
were present in the tumor cells, e.g., by electrophysiological
recording, nor did they provide evidence to indicate whether
the drugs elicited their effects through VGSC inhibition
or another, VGSC-independent mechanism. The third study
(Anderson et al., 2003) showed that phenytoin and several
other inhibitors (hydroxyamides and a hydantoin) reduced
proliferation of an androgen-independent prostate cancer cell
line, without significantly affecting viability. The authors also
showed that the drugs inhibited Na+ current (i.e., VGSC
functional activity) in Xenopus oocytes expressing Nav1.2,
although they did not show whether the drugs inhibited
endogenous VGSC activity in the prostate cancer cells. In
the fourth study (Yang et al., 2012), we reported that
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TABLE 2 | Summary of included studies.
Reference Population Study design Intervention Outcome Score /5
Raderer et al., 1993 Fourteen females
with advanced
refractory breast
cancer
Phase I/II clinical trial of
quinidine and
pirarubicin
Two-hundred and fifty
milligram quinidine
bisulphate twice daily
for 5 days. Cycle
repeated every
3–4 weeks.
Stable disease in
six patients,
progression in eight
patients
4
Wheler et al., 2014 Fifty-seven patients
with colorectal
(51%), prostate
(10%), breast (9%),
or other cancer
(31%)
Phase I trial of
bevacizumab and VPA
in patients with
untreatable advanced
cancer
Valproic acid 5.3 mg/kg
once
daily + bevacizumab
11 mg/kg every
14 days
Safe combination.
Improved overall
survival if
hypertension
present
4
Abdul and Hoosein, 2001 LNCaP, PC-3 and
DU-145 prostate
cancer cell lines
In vitro study of drug
effect on proliferation
Phenytoin,
carbamazepine,
valproate
Drugs inhibited
proliferation at
clinically relevant
doses
4
Abdul and Hoosein, 2002 LNCaP, PC-3,
DU-145, and
MDA-PCA-2B
prostate cancer cell
lines
In vitro study of drug
effect on proliferation
Riluzole Riluzole inhibited
proliferation
4
Anderson et al., 2003 PC-3 Compound discovery
of phenytoin analogs
Phenytoin and analogs Phenytoin and
synthesized
analogs inhibit
proliferation
4
Driffort et al., 2014 Spontaneous
metastasis murine
model using
MDA-MB-231
breast cancer cells
In vivo study of drug
effect on lung
metastasis
Ranolazine Ranolazine inhibits
lung metastasis
in vivo and Na+
current, invasion
and extracellular
matrix degradation
in vitro
4
Nelson et al., 2015 Orthotopic murine
breast cancer
model using
MDA-MB-231
breast cancer cells
In vivo study of drug
effect on breast tumor
growth, invasion, and
metastasis
Phenytoin 60 mg/kg
once daily
At clinically relevant
dose, phenytoin
reduces tumor
growth,
proliferation,
invasion, and
metastasis
4
Yang et al., 2012 MCF-7 and
MDA-MB-231
breast cancer cells
In vitro study of drug
effect on Na+ current,
migration, and invasion
Phenytoin Phenytoin inhibits
migration and
invasion of
VGSC-expressing
MDA-MB-231 cells
4
Al Snafi et al., 2014 AMN-3 breast
cancer cells
In vitro study of drug
effect on cell viability
Valproate Valproate inhibits
cell proliferation
3
Angelucci et al., 2006 LNCaP, DU145,
PC-3 prostate
cancer cells
In vitro study of drug
effect on growth and
apoptosis
Valproic acid and
butyrate analogs
Valproic acid
inhibits cell growth
and stimulates
programmed cell
death
3
Chang et al., 2014 MCF-7 mammary
carcinoma and
MCF-10A epithelial
cells
In vitro study of drug
effect on apoptosis
Lidocaine,
tetracaine
Drugs inhibited
morphological
changes but were
not pro-apoptotic
3
Fortunati et al., 2008 MCF-7, ZR-75-1,
MDA-MB-231, and
MDA-MB-435
breast cancer cells
In vitro study of drug
effect on proliferation
Valproic acid Valproic acid
inhibited
proliferation in
estrogen-sensitive
breast cancer cells
3
(Continued)
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TABLE 2 | Continued
Reference Population Study design Intervention Outcome Score /5
Iacopino et al., 2008 LNCaP; PC-3
prostate cancer
cells
In vitro study of drug
effect on proliferation
Valproic acid Valproic acid
inhibited
proliferation in both
cell lines to a
variable extent
3
Jafary et al., 2014 MCF-7 breast
cancer cells
In vitro study of drug
effect on proliferation
Valproic
acid + nicotinamide
Drug combination
inhibited
proliferation,
increased
apoptosis
3
Jawed et al., 2007 MCF-7 breast
cancer cells
In vitro study of drug
effect on proliferation
Valproic
acid + melatonin
Valproic acid
inhibited
proliferation in
presence/absence
of melatonin
3
Jiang et al., 2014 PC3, DU145
prostate cancer
cells
In vitro study of drug
effect on invasion and
SMAD4 activity
Valproic acid Valproic acid
inhibited invasion
through AKT
pathway
3
Li et al., 2012 MDA-MB-231
breast cancer cells
In vitro study of drug
effect on cell behaviors
Valproic acid Valproic acid
inhibited cell
migration but not
proliferation
3
Li et al., 2014 MCF-7 and
MDA-MB-231
breast cancer cells
In vitro study of drug
effect on apoptosis
Lidocaine + cisplatin Lidocaine
enhanced
cisplatin-induced
apoptosis
3
Olsen et al., 2004 MCF-7 In vitro study of drug
effect on proliferation
Phenytoin,
phenobarbital, valproic
acid, lamotrigine
Phenytoin,
phenobarbital, and
valproic acid
inhibited
proliferation,
whereas
lamotrigine did not
3
Papi et al., 2012 HT-29 and LoVo
colon carcinoma
cells
In vitro study of drug
effect on proliferation,
invasion, and apoptosis
Valproic acid + rexinoid
IIF
Drug combination
inhibited cell growth
and invasion,
induced apoptosis
3
Wedel et al., 2011 LNCaP; PC-3
prostate cancer
cells
In vitro study of drug
effect on cell behavior
Valproic acid + mTOR
inhibitor RAD001
Valproic acid and
RAD001 reduced
cell adhesion and
migration
3
Yoon et al., 2011 MCF10A,
MCF10A-Bcl2,
MDA-MB-436
breast epithelial,
and cancer cells
In vitro study of drug
effect on cell behavior
Tetracaine, lidocaine Tetracaine and
lidocaine inhibit
microtentacle
attachment,
microfilament
organization, and
cell adhesion
3
Zhang et al., 2011 RM-1 prostate
cancer cells
In vitro study of drug
effect on
E-cadherin-mediated
cell migration
Valproic acid Valproic acid
promoted
E-cadherin
expression and
inhibited cell
migration.
3
Zhang et al., 2012 MDA-MB-231
breast cancer cells
In vitro study of drug
effect on cell behavior
Valproic acid Valproic acid
inhibited cell
migration with
clinically relevant
doses
3
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FIGURE 2 | Scoring of included studies. Study quality and evidence was quantified in the included studies (2 clinical and 22 preclinical) according to the modified
standardized pre-piloted criteria assessment tool in Supplementary Table S3. Maximum score = 5, minimum score for inclusion in systematic review = 3.
phenytoin inhibited Na+ current, migration and invasion
of metastatic MDA-MB-231 breast cancer cells at clinically
relevant doses, although it had no effect on cell proliferation.
Importantly, phenytoin had no effect on proliferation, migration
or invasion of weakly metastatic MCF-7 cells, which do
not express Na+ currents, suggesting that the effect of
phenytoin is VGSC-dependent (Yang et al., 2012). All four
studies suggest that further in vivo studies are warranted
to explore the effect of VGSC-inhibiting drugs on cancer
progression/metastasis.
There were two recent in vivo preclinical studies testing the
effect of VGSC-inhibiting drugs on breast cancer metastasis
in mice, which both scored 4 out of 5. In Nelson et al.
(2015), we showed that phenytoin slowed tumor growth, local
invasion and metastasis in an orthotopic mouse breast cancer
model. In addition, Driffort et al. (2014) showed that ranolazine
reduced lung colonization in an experimental metastasis mouse
model of breast cancer. In the same study, ranolazine was also
found to inhibit Na+ current, invasion and extracellular matrix
degradation in vitro. Importantly, the effect of ranolazine on
metastasis was equivalent to that of Nav1.5 down-regulation with
shRNA, suggesting that the metastasis-inhibiting effect of this
drug is VGSC-dependent.
The remaining 17 studies scored 3 of 5 since they did
not specifically look into the VGSC-inhibiting activity of the
interventions. The most commonly tested drug was sodium
valproate (13 studies) and the most common cell line breast
cancer (11 studies). Not all drugs in these studies were tested
at clinically relevant dosages, thus making the interpretation
of some results and their clinical relevance challenging. For
example, one study treated breast cancer cells with lidocaine in
the range 0.01–1 mM (Li et al., 2014). However, lidocaine toxicity
in humans has been reported at doses ≥0.04 mM (Collinsworth
et al., 1974). Another study treated a range of tumor cell lines
with sodium valproate at concentrations up to 10 times higher
than the therapeutic range of 50–125 µg/ml, although growth
inhibition was also observed at doses as low as 31 µg/ml for
some, but not all cell lines tested (Al Snafi et al., 2014). Overall
six studies reported pro-apoptotic effects, eight inhibition of cell
proliferation, five inhibition of migration, and four inhibition
of invasion. Four studies reported no effects on proliferation
(Figures 3A–E).
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FIGURE 3 | Study distribution by cancer type, intervention and outcome measure. (A) Number of studies (%) on humans, animals and cell lines. (B) Number
of studies (%) testing monotherapy vs. those testing multiple drugs in combination. (C) Number of studies (%) on breast, colon and prostate cancer. (D) Studies (%)
divided by drug type. (E) Studies (%) divided by outcome measure.
DISCUSSION
It is known that VGSCs are expressed in metastatic cells
in various tumor types (Brackenbury, 2012). In addition, a
number of studies using the (non-therapeutic) VGSC-blocking
neurotoxin tetrodotoxin (Grimes et al., 1995; Laniado et al.,
1997; Fraser et al., 1999, 2003, 2004, 2005; Roger et al., 2003;
Brackenbury and Djamgoz, 2006), gene knockdown, e.g., siRNA
(Brackenbury et al., 2007; House et al., 2010; Brisson et al., 2013),
or over-expression approaches (Bennett et al., 2004; Chioni et al.,
2009), have generated considerable mechanistic insight into the
role of VGSCs in metastatic cancer cells, reviewed in detail
elsewhere (Fraser et al., 2014a; Besson et al., 2015). The purpose
of this study was to systematically investigate current clinical
evidence that VGSC-inhibiting drugs slow cancer progression,
e.g., by inhibiting tumor growth and/or metastasis. Our initial
aim was to focus on human studies, however, we soon discovered
a scarcity of human data in this field. We therefore expanded our
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search to preclinical studies. To our knowledge this is the first
systematic review in this field of interest.
Twenty-four studies met the inclusion criteria and attained
high quality scores (≥3/5). Two were clinical drug trials, one
of which was conducted in 1993 at a time when VGSC
expression in cancer cells was not yet widely appreciated and
therefore the VGSC-inhibiting mode of action of quinidine
was not specifically investigated (Raderer et al., 1993). The
second, more recent study investigated the HDAC inhibitory
effects of sodium valproate as an adjuvant and its possible
beneficial effect on survival (Wheler et al., 2014). Both
studies included advanced disease, which would preclude
the observation that VGSC inhibitors may elicit early anti-
metastatic effects by slowing invasion and/or preventing cancer
progression. Indeed, most systemic anti-metastatic therapies
capitalize on the understanding of late stages of the metastatic
cascade, once tumor cells have already spread to secondary
sites (Mina and Sledge, 2011), so a VGSC-targeting therapy
may be highly novel. Although the lack of clinical data
was disappointing, the systematic review of preclinical data
allowed us to expose the broad range of VGSC inhibitors
that have now been tested in various models as potential
anti-cancer drugs. We discovered that a variety of modes
of action were tested/postulated, and there was a notable
lack of standardization in the outcome measures that were
captured.
A key theme of the preclinical in vitro studies was that
various VGSC inhibitors generally had an inhibitory effect
on proliferation of cancer cells, and/or promoted apoptosis,
either alone, or in combination with other chemotherapeutic
agents. In the majority of cases, the VGSC-inhibiting mode
of action of these drugs was not tested/identified. Indeed,
the mode of action of the most commonly studied VGSC-
inhibiting drug, sodium valproate, was shown to be, at
least partially, through HDAC inhibition in several studies
(Angelucci et al., 2006; Zhang et al., 2011, 2012; Papi
et al., 2012). Whilst this explanation is highly plausible,
it cannot be excluded that valproate may also elicit its
anti-tumor effects through additional mechanisms, including
VGSC inhibition. In support of this notion, taking the
general observation that different VGSC-inhibiting drugs,
not all of which are HDAC inhibitors, have similar anti-
cancer properties, their effects may be through another
common mechanism, i.e., VGSC inhibition. A similar situation
may occur for the Ca2+ channel blockers verapamil and
diltiazem: these drugs elicit an anticancer effect by inhibiting
P glycoprotein and multidrug resistance, but have also been
shown to inhibit VGSCs in metastatic breast cancer cells (Roger
et al., 2004). Further work is required to investigate these
possibilities.
There were several key weaknesses with a number of the
in vitro studies. Firstly, the methodology and outcome measures
were not standardized across different studies, and interpretation
of some measures was inconsistent, e.g., a relative reduction
in cell number was variously interpreted as a reduction in
proliferation, an increase in apoptosis, or an increase in
cytotoxicity across different studies. Secondly, drug dosing was
highly variable across different studies. Whilst some carefully
reported the measured dose was within the therapeutic range
for other indications (Yang et al., 2012; Nelson et al., 2015),
others did not, and in several cases the dose was orders of
magnitude above the therapeutic range (Al Snafi et al., 2014;
Li et al., 2014), with the risk that the reported effects may be
due to non-specific cytotoxicity. Clearly, further work is required
to standardize dosing regimen across different in vitro models
in order to unequivocally establish whether or not these drugs
do indeed inhibit metastatic cell behaviors in different cancer
cell types. Finally, the in vitro studies have generally focused on
tumor cell lines in isolation without taking into consideration
the possible effect of VGSC-inhibiting drugs on other cells
in the heterogeneous tumor microenvironment, e.g., immune
cells, or possible drug–drug interactions with concurrently
administered chemotherapeutic agents (Vecht et al., 2003; Lo
et al., 2012).
Despite the relatively large number of in vitro studies,
our search revealed only two in vivo studies where VGSC
inhibitors have been tested in mouse models (Driffort et al.,
2014; Nelson et al., 2015). Both these studies employed xenografts
of MDA-MB-231 breast cancer cells into immunocompromised
mice, although one involved implantation at the orthotopic
site and the other tail vein injection (spontaneous metastasis).
Interestingly, both models showed a similar result, that the
VGSC-inhibiting drugs tested inhibited metastatic dissemination
of breast cancer cells. Similar to the in vitro studies, one
weakness with these in vivo models is that they cannot consider
the effects of the drugs on cell–cell interaction in a complex
tumor microenvironment in immune-competent hosts (Vargo-
Gogola and Rosen, 2007). Nonetheless, it is worthy to note here
that one study has shown that the VGSC-inhibiting neurotoxin
tetrodotoxin, not licensed for clinical use, so excluded from
our review, inhibits lung metastasis in a rat prostate cancer
allograft model, an immunocompetent host (Yildirim et al.,
2012).
It is important to note that several studies have shown
that compounds not classically considered as VGSC-inhibiting
therapeutic agents, e.g., the natural plant phenolic resveratrol
and the omega-3 long chain polyunsaturated docosahexaenoic
acid, reduce VGSC-dependent cancer cell migration and invasion
(Isbilen et al., 2006; Fraser et al., 2014b; Wannous et al.,
2015). In addition, recent evidence suggests that anesthetics that
target VGSCs, e.g., ropivacaine, may also inhibit cancer cell
invasion (Baptista-Hon et al., 2014). Furthermore, the voltage-
gated Ca2+ channel-targeting antiepileptic drug gabapentin,
which may also inhibit VGSCs (Zhang et al., 2013), has recently
been shown to inhibit invasion and metastasis of prostate
cancer cells at high doses (Bugan et al., 2015). Finally, a recent
study published in June 2015 (after the search period ended)
has shown that lidocaine inhibits Na+ current, extracellular
signal-regulated kinase (ERK) phosphorylation and cellular
invasion of SW620 colorectal cancer cells in vitro (House et al.,
2015). Thus, VGSC inhibition via the use of various agents
beyond the scope of this review may also have therapeutic
value, and further work is required to establish this possibility
in vivo.
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Based on this review, we make the following
recommendations: Firstly, future clinical studies need to directly
investigate the VGSC-inhibitory effects of relevant drugs using
electrophysiological recording as an outcome measure. Second,
clinically relevant in vivo models are needed to identify the
most potent and safest VGSC-inhibiting drugs as anti-metastatic
agents. Thirdly, methodology and outcome measures need to
be standardized in order to be able to comparison of outcomes
across tumor types and drugs. Finally, specific quality assessment
tools are needed to evaluate in vitro studies of clinical interest.
CONCLUSION
There is only one registered clinical trial in cancer patients
specifically exploring the anti-tumor effects of licensed VGSC
blockers on survival. The study in question is a randomized
open-label trial in India exploring the effect of lidocaine
administration during surgery on disease-free survival of patients
with operable breast cancer and will not complete until 2019
(ClinicalTrials.gov Identifier: NCT01916317). Given the large
and growing body of preclinical evidence in favor of VGSC
inhibitors as anti-tumor and anti-metastatic agents, clinical
trials are urgently needed to explore this novel therapeutic
angle in breast, colorectal, and prostate cancer patients. Novel
agents that preferentially target the neonatal splice variant
of VGSCs expressed in these adult cancers (Fraser et al.,
2005; Baptista-Hon et al., 2014) should be developed and
assessed. In addition, a number of the VGSC inhibitors
investigated here are already licensed for non-cancer and
cancer indications and could repurposed in phase 2 trials
specifically investigating their VGSC inhibitory and anti-cancer
properties.
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